Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response statements are fully consistent with the FDA label regarding weight-based dosing (mg/kg) and a fixed cycle schedule (every 3 weeks). However, the response omits safety, administration, and broader labeling details that are present in the official labeling.
Category Scores
Accurate Statements
Enhertu dosing is weight-based (mg/kg) per label.
2.2; Table 1 shows dosing in mg/kg (e.g., 5.4 mg/kg every 3 weeks).
Dosing is given on a set cycle schedule (every 3 weeks).
2.2; Table 1 specifies every 3 weeks; Cycle 1, Day 1 references.
Unsupported Statements
Contradictions
Important Omissions
Safety and administration details such as infusion-related reaction management, antiemetic guidance, premedication, boxed warnings (ILD/pneumonitis, embryo-fetal toxicity), pregnancy/pediatric considerations, and contraindications are not addressed in the claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims focus solely on dosing cadence and weight-based dosing; no safety information is provided. The label contains significant safety warnings that are not discussed in the claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing safety/administration context in the two claims
Suggested Improvement
Incorporate critical safety warnings (e.g., boxed warnings for ILD/pneumonitis and embryo-fetal toxicity), pregnancy/pediatric considerations, infusion-related reaction management, antiemetic guidance, premedication, and explicit administration instructions alongside the dosing claims.